Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature
COVID-19 hydroxychloroquine tocitizumab anakinra baricitinib antirheumatic agents cytokine storm pathogenesis azithromycin combination General & Internal Medicine
; 2021(Revista Del Cuerpo Medico Del Hospital Nacional Almanzor Aguinaga Asenjo)
Article
in Spanish
| WHO COVID | ID: covidwho-1237073
ABSTRACT
We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and supportive. Therefore, this review will study the most prominent antirheumatic drugs that have a probable pharmacological effect, such as hydroxychloroquine, tocitizumab, anakinra and baricitinib, against COVID-19. It is expected that they wilt provide support for future treatments. and research on the disease.
Full text:
Available
Collection:
Databases of international organizations
Database:
WHO COVID
Topics:
Vaccines
Language:
Spanish
Journal:
COVID-19 hydroxychloroquine tocitizumab anakinra baricitinib antirheumatic agents cytokine storm pathogenesis azithromycin combination General & Internal Medicine
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS